Cervical cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 1, 2008, Pages 14-36

  Greer, Benjamin E ^a   Koh, Wui Jin ^a   Abu Rustum, Nadeem R ^b   Bookman, Michael A ^c   Bristow, Robert E ^d   Campos, Susana ^e   Cho, Kathleen R ^f   Copeland, Larry ^g   Eifel, Patricia ^h   Huh, Warner K ⁱ   Jaggernauth, Wainwright ^j   Kapp, Daniel S ^k   Kavanagh, John ^h   Lipscomb, Gary H ^l   Lurain III, John R ^m   Morgan, Mark ^c   Morgan Jr , Robert J ⁿ   Powell, C Bethan ^o   Remmenga, Steven W ^p   Reynolds, R Kevin ^f   Secord, Angeles Alvarez ^q   Small Jr , William ^m   Teng, Nelson ^k   more..

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j ROSWELL PARK CANCER INSTITUTE   (United States)

^k STANFORD CANCER INSTITUTE   (United States)

^l UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ City of Hope ^*

^o UNIVERSITY OF CALIFORNIA   (United States)

^p NEBRASKA MEDICAL CENTER   (United States)

^q DUKE CANCER INSTITUTE   (United States)

more..

Author keywords

Cervical cancer; Chemotherapy; Human papillomavirus; Hysterectomy; NCCN clinical practice guidelines; Radiation therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; TOPOTECAN; WART VIRUS VACCINE;

BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR BIOPSY; UTERINE CERVIX CANCER;

EID: 38949136630     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0003     Document Type: Review

References (69)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711-1742.
3. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005;103:1258-1264.
4. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
5. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150.
6. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278.
7. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-1868.
8. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.
9. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007;38:189-197.
10. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas. Int J Gynaecol Obstet 2002;78:79-91.
11. Chi DS. Laparoscopy in gynecologic malignancies. Oncology 1999;13:773-782.
12. Benedet JL, Bender H, Jones H III, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-262.
13. Landoni F, Maneo A, Colombo A, et al. Randomized study of radical surgery vs. radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-540.
14. Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2804-2810.
15. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007;25:2952-2965.
16. Pearcey R, Miao Q, Kong W, et al. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study. J Clin Oncol 2007;25:2383-2388.
17. Haie-Meder C, Fervers B, Fondrinier E, et al. SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update bulletin 2004. Ann Oncol 2005;16:1100-1108.
18. Koliopoulos G, Sotiriadis A, Kyrgiou M, et al. Conservative surgical methods for FIGO stage IA2 squamous cervical carcinoma and their role in preserving women's fertility. Gynecol Oncol 2004;93:469-473.
19. Bernardini M, Barrett J, Seaward G, et al. Pregnancy outcomes in patients after radical trachelectomy. Am J Obstet Gynecol 2003;189:1378-1382.
20. Boss EA, van Golde RJ, Beerendonk CC, et al. Pregnancy after radical trachelectomy: a real option? Gynecol Oncol 2005;99:S152-156.
21. Plante M, Renaud MC, Hoskins IA, Roy M. Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 2005;98:3-10.
22. Marchiole P, Benchaib M, Buenerd A, et al. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH). Gynecol Oncol 2007;106:132-141.
23. Shepherd JH, Spencer C, Herod J, Ind TE. Radical vaginal trachelectomy as a fertility-spating procedure in women with early-stage cervical cancer-cumulative pregnancy rate in a series of 123 women. BJOG 2006;113:719-724.
24. Landoni F, Zanagnolo V, Lovato-Diaz L, et al. Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study). Int J Gynecol Cancer 2007;17:623-628.
25. Shimada M, Kigawa J, Nishimura R, et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol 2006;101:234-237.
26. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-1161.
27. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143.
28. Peters WA III, Liu PY, Barrett RJ II, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-1613.
29. Chernofsky MR, Felix JC, Muderspach LI, et al. Influence of quantity of lymph vascular space invasion on time to recurrence in women with early-stage squamous cancer of the cervix. Gynecol Oncol 2006;100:288-293.
30. Marchiola P, Buenerd A, Benchaib M, et al. Clinical significance of lymphovascular space involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective case-control surgico-pathological study. Gynecol Oncol 2005;97:727-732.
31. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy vs. no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol 1999;73:177-183.
32. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006;65:169-176.
33. Thomas GM, Dembo AJ, Myhr T, et al. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer 1993;3:193-198.
34. Averette HE, Lichtinger M, Sevin BU, et al. Pelvic exenteration: a 15-year experience in general metropolitan hospital. Am J Obstet Gynecol 1984;150:179-184.
35. Morley GW. Pelvic exenteration in the treatment of recurrent cervical cancer. In: Heints APM, Griffiths CT, Trimbos JB, editors. Surgery in Gynecological Oncology. The Hague: Martinus Nijhoff; 1984:174.
36. Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Gtoup. Cancer 1981;48:899-903.
37. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;32:198-202.
38. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14:792-795.
39. Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000;77:446-449.
40. Dubay RA, Rose PG, O'Malley DM, et al. Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol 2004;94:121-124.
41. Muderspach LI, Blessing JA, Levenback C, et al. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2001;81:213-215.
42. Higgins RV, Naumann WR, Hall JB, et al. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol 2003;89:499-503.
43. Coleman RE, Harper PG, Gallagher C, et al. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1986;18:280-283.
44. Sutton GP, Blessing JA, McGuire WP, et al. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993;168:805-807.
45. Muggia FM, Blessing JA, Method M, et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:639-643.
46. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15:625-631.
47. Wong LC, Ngan HY, Cheung ANY, et al. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol 1999;17:2055-2060.
48. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IV, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:3113-3119.
49. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005;23:4626-4633.
50. Burnett AF, Roman LD, Garcia AA, et al. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, ot recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 2000;76:63-66.
51. Sit AS, Kelley JL, Gallion HH, et al. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix. Cancer Invest 2004;22:368-373.
52. Gebbia V, Caruso M, Testa A, et al. Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervix. Oncology 2002;63:31-37.
53. Vermorken JB. The role of chemotherapy in squamous-cell carcinoma of the uterine cervix: a review. Int J Gynecol Cancer 1993;3:129-142.
54. Lopez A, Kudelka AP, Edwards CL, et al. Carcinoma of the uterine cervix. In: Pazdur R, editor. Medical Oncology: A Comprehensive Review. Huntington, New York: PRR; 1996:393-405.
55. Thomas GM. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med 1999;340:1198-1200.
56. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin vs. hydroxyurea as an adjunct to radiation therapy in stage IIB-IIIA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-1348.
57. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153.
58. Lanciano R, Calkins A, Bundy BN, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 2005;23:8289-8295.
59. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group Trial (RTOG) 90-01. J Clin Oncol 2004;22:872-880.
60. Committee on Adolescent Health Care; ACOG Working Group on Immunization. ACOG Committee Opinion No. 344: human papillomavirus vaccination. Obstet Gynecol 2006;108(3 Pt 1):699-705.
61. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2):1-24.
62. Saslow D, Castle PE, Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7-28.
63. Sadler L, Saftlas A, Wang W, et al. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004;291:2100-2106.
64. Samson SL, Bentley JR, Fahey TJ, et al. The effect of loop electrosurgical excision procedure on future pregnancy outcome. Obstet Gynecol 2005;105:325-332.
65. Jakobsson M, Gissler M, Sainio S, et al. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2007;109(2 Pt 1):309-313.
66. Sjaborg KD, Vistad I, Myhr SS, et al. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet Gynecol Scand 2007;86:423-428.
67. Swensen RE, Goff BA, Koh WJ, et al. Cancer in the pregnant patient. In: Principles and Practice of Gynecologic Oncology, 4th edition. Hoskins WJ, Perez CA, Young RC, et al., eds. Philadelphia: Lippincott Williams & Wilkins; 2004.
68. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004;5:283-291.
69. Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007;25:2975-2982.